NCT00301392|CompletedPhase 4
Loading search results
Sponsor study identifier
interventional
1,240
1 country
1
Study Start
April 2006
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
March 2012
Actual (reported)Study Completion
June 2012
Actual (reported)The purpose of this study is to evaluate the effects of pitavastatin for preventing diabetes in a population with impaired glucose tolerance.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 2012
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 5, 2006
Actual (reported)March 10, 2006
Actual (reported)April 2006
Date type not reportedThis date has not been verified as actual or estimated.
March 2012
Actual (reported)June 2012
Actual (reported)Cumulative incidence of diabetes based on 1 positive OGTT or fasting glucose levels
from April, 2006 to end of March, 2012
Incidence of newly developed diabetes
from April, 2006 to end of March, 2012
Cumulative incidence of diabetes based on clinical diagnosis.
from April, 2006 to end of March, 2012
Cumulative incidence of newly developed diabetes based on 1 positive OGTT or fasting glucose levels
from April, 2006 to end of March, 2012
Time until development of diabetes; Improvement in glucose tolerance
from April, 2006 to end of March, 2012
Incidence of any cardiovascular disease (myocardial infarction, angina, congestive heart disease, coronary revascularization, cerebral hemorrhage, cerebral infarction.
from April, 2006 to end of March, 2012
Administration of Pitavastatin
As the life-style interventions aiming to reduce the major risks of developing diabetes mellitus, instruct the following four items:(1)set diet right, (2)maintain normal weight,(3)improve physical activity,(4)normalize smoking and alcohol drinking.
Once-daily dosing of pitavastatin 1 mg(1 tablet of Livalo Tab 1 mg), or 2mg(2 tablets of Livalo Tab 1mg or 1 tablet of Livalo Tab 2mg);Dosing period of pitavastatin should be 60 months.(max.84 months).
The University of Tokyo, Graduate School of Medicine
Bunkyo-ku, Tokyo, 113-8655, Japan
Takashi Kadowaki, MD,PhD
Professor, Department of Metabolic Diseases, Graduate School of Medicine, the University of Tokyo.
1,240 participants (actual enrollment reported by the registry).
First Submitted
March 5, 2006
First Posted
March 10, 2006
Study Start
April 2006
Date type not reportedThis date has not been verified as actual or estimated.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
March 2012
Actual (reported)Study Completion
June 2012
Actual (reported)Last Updated
September 6, 2013
Record last verified: 2013-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: